This NIH program funds pre-clinical and early Phase I development of new drug candidates to prevent, slow, or treat Alzheimer's disease, covering medicinal chemistry, PK/ADMET, animal efficacy, biomarkers, GMP synthesis, IND-enabling studies, and Phase I testing. It is for organizations with an actual Alzheimer's drug candidate in hand, not for basic research, diagnostics, devices, repurposed drugs, or non-drug interventions. Retail, construction, finance, and other businesses with no drug-derel
| Industry | Estimated fit |
|---|---|
| Healthcare & BiotechMatches your industry (clinical) | 85 |
| Education & TrainingMatches your industry (training) | 70 |
| Agriculture & FarmingLimit: Nothing in this notice points to agriculture & farming | 54 |
| Arts & CultureLimit: Nothing in this notice points to arts & culture | 54 |
| Energy & Clean TechLimit: Nothing in this notice points to energy & clean tech | 54 |
| Environment & ConservationLimit: Nothing in this notice points to environment & conservation | 54 |
| Industry | Estimated fit |
|---|---|
| Finance & BankingLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| Food & BeverageLimit: Nothing in this notice points to food & beverage | 54 |
| Housing & Real EstateLimit: Nothing in this notice points to housing & real estate | 54 |
| ManufacturingMatches your industry (manufacturing) | 54 |
| Retail & E-CommerceLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| Social Services & NonprofitLimit: Nothing in this notice points to social services & nonprofit | 54 |
| Technology & SoftwareLimit: Nothing in this notice points to technology & software | 54 |
| Transportation & LogisticsLimit: Not clearly about your industry or what you need funding for; check the… | 54 |
| Construction & InfrastructureLimit: Nothing in this notice points to construction & infrastructure | 52 |
These are our matcher’s estimates for a typical business in each industry. A real match depends on your size, your state and what you need the money for — check your own fit.
NIH program funding pre-clinical and early Phase I development of novel small-molecule and biologic drug candidates to prevent, slow, or treat Alzheimer's disease. Open to small businesses, for-profits, nonprofits, universities, and state/local/tribal governments; funds medicinal chemistry, PK/ADMET, animal efficacy, biomarkers, GMP synthesis, IND-enabling studies, and Phase I testing.
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Topics
Open opportunities funding similar work, from the same funder or in the same place.
NIH BRAIN Initiative grants to develop tools and computational models for high-resolution, synchronous measurement of complex behaviors alongside neural activity in humans and other species. Eligible applicants include…
NIH/NCI K99/R00 career-development award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent tenure-track faculty positions; requires the candidate to lead an…
NIH/NCI UH3 cooperative agreement to clinically validate established molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, or treatment response using specimens from…
NIH/NCI K99/R00 award for early-stage postdoctoral researchers (with research or clinical doctorates) transitioning to independent faculty careers. The applicant is typically the sponsoring institution; eligible…
NIH/NCI cooperative agreement (UH2/UH3) funding validation of molecular, cellular, and imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response. Open to universities,…
NIH/NCI program funding revision applications to adapt and clinically validate molecular, cellular, or imaging biomarker assays for cancer detection, diagnosis, prognosis, monitoring, and treatment response prediction.…